Lack of resistant mutation development after receiving short-course zidovudine plus lamivudine to prevent mother-to-child transmission.
A short-course regimen of zidovudine plus lamivudine starting from 34 weeks' gestation in pregnant women to prevent mother-to-child HIV infection, and discontinued after delivery, was evaluated for the development of resistance at 6 weeks postpartum. No resistant mutation was found in 32 women. One of the three infected infants carried the M184V and K219Q mutations.
Chokephaibulkit
Kulkanya
K
Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chaisilwattana
Pongsakdi
P
Vanprapar
Nirun
N
Phongsamart
Wanatpreeya
W
Sutthent
Ruengpung
R
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D024882:Drug Resistance, Viral / Q000235:genetics*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019259:Lamivudine / Q000008:administration & dosage*; D009154:Mutation / Q000235:genetics*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*; D015215:Zidovudine / Q000008:administration & dosage*
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine